1601P Estimated years of potential life lost due to absence of pembrolizumab in SUS

Abstract

percentage of TNBC of 31.3% (16.7% for the whole group). For all patients, advanced stages were mostly seen outside the capital (60.4% in Bekaa and 54.7% in North Lebanon). The trend of early stages at diagnosis (I and II) decreased from 55.6% in 2012 to 41.9% in 2017, while advanced stages increased from 44.4% to 57.9% during the same time period.Conclusions: Breast cancer downstaging through screening mammography of Lebanese patients was not achieved. Early detection of breast cancer has not shown any improvement over the period investigated. Implementation of genetic testing and tailored approaches to Lebanese women are recommended for future campaigns. In addition, reallocation of the MOPH breast cancer budget to more suitable screening tests and alternative care delivery strategies is suggested.Legal entity responsible for the study: The authors.